TY - JOUR
T1 - Three-Year Interval for the Multi-Target Stool DNA Test for Colorectal Cancer Screening
T2 - A Longitudinal Study
AU - Imperiale, Thomas F.
AU - Lavin, Philip T.
AU - Marti, Tara N.
AU - Jakubowski, Debbie
AU - Itzkowitz, Steven H.
AU - May, Folasade P.
AU - Limburg, Paul J.
AU - Sweetser, Seth
AU - Daghestani, Anas
AU - Berger, Barry M.
N1 - Publisher Copyright:
©2022 The Authors; Published by the American Association for Cancer Research
PY - 2023/2
Y1 - 2023/2
N2 - Data supporting the clinical utility of multi-target stool DNA (mt-sDNA) at the guideline-recommended 3-year interval have not been reported. Between April 2015 and July 2016, candidates for colorectal cancer screening whose providers prescribed the mt-sDNA test were enrolled. Participants with a positive baseline test were recommended for colonoscopy and completed the study. Those with a negative baseline test were followed annually for 3 years. In year 3, the mt-sDNA test was repeated and colonoscopy was recommended independent of results. Data were analyzed using the Predictive Summary Index (PSI), a measure of the gain in certainty for dichotomous diagnostic tests (where a positive value indicates a net gain), and by comparing observed versus expected colorectal cancers and advanced precancerous lesions. Of 2,404 enrolled subjects, 2,044 (85%) had a valid baseline mt-sDNA result [284 (13.9%) positive and 1,760 (86.1%) negative]. Following participant attrition, the year 3 intention to screen cohort included 591 of 1,760 (33.6%) subjects with valid mt-sDNA and colonoscopy results, with no colorectal cancers and 63 advanced precancerous lesions [22 (34.9%) detected by mt-sDNA] and respective PSI values of 0% (P ¼ 1) and 9.3% (P ¼ 0.01). The observed 3-year colorectal cancer yield was lower than expected (one-sided P ¼ 0.09), while that for advanced precancerous lesions was higher than expected (two-sided P ¼ 0.009). Repeat mt-sDNA screening at a 3-year interval resulted in a statistically significant gain in detection of advanced precancerous lesions. Due to absence of year 3 colorectal cancers, the PSI estimate for colorectal cancer was underpowered and could not be reliably quantified. Larger studies are required to assess the colorectal cancer study findings.
AB - Data supporting the clinical utility of multi-target stool DNA (mt-sDNA) at the guideline-recommended 3-year interval have not been reported. Between April 2015 and July 2016, candidates for colorectal cancer screening whose providers prescribed the mt-sDNA test were enrolled. Participants with a positive baseline test were recommended for colonoscopy and completed the study. Those with a negative baseline test were followed annually for 3 years. In year 3, the mt-sDNA test was repeated and colonoscopy was recommended independent of results. Data were analyzed using the Predictive Summary Index (PSI), a measure of the gain in certainty for dichotomous diagnostic tests (where a positive value indicates a net gain), and by comparing observed versus expected colorectal cancers and advanced precancerous lesions. Of 2,404 enrolled subjects, 2,044 (85%) had a valid baseline mt-sDNA result [284 (13.9%) positive and 1,760 (86.1%) negative]. Following participant attrition, the year 3 intention to screen cohort included 591 of 1,760 (33.6%) subjects with valid mt-sDNA and colonoscopy results, with no colorectal cancers and 63 advanced precancerous lesions [22 (34.9%) detected by mt-sDNA] and respective PSI values of 0% (P ¼ 1) and 9.3% (P ¼ 0.01). The observed 3-year colorectal cancer yield was lower than expected (one-sided P ¼ 0.09), while that for advanced precancerous lesions was higher than expected (two-sided P ¼ 0.009). Repeat mt-sDNA screening at a 3-year interval resulted in a statistically significant gain in detection of advanced precancerous lesions. Due to absence of year 3 colorectal cancers, the PSI estimate for colorectal cancer was underpowered and could not be reliably quantified. Larger studies are required to assess the colorectal cancer study findings.
UR - http://www.scopus.com/inward/record.url?scp=85147458308&partnerID=8YFLogxK
U2 - 10.1158/1940-6207.CAPR-22-0238
DO - 10.1158/1940-6207.CAPR-22-0238
M3 - Article
C2 - 36205504
AN - SCOPUS:85147458308
SN - 1940-6207
VL - 16
SP - 89
EP - 97
JO - Cancer Prevention Research
JF - Cancer Prevention Research
IS - 2
ER -